NCT00896064View on ClinicalTrials.gov

Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 18, 2009

Primary Completion Date

August 5, 2009

Study Completion Date

August 5, 2009

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK2189242A (formulation 1)

One dose will be administered intramuscularly at Study Day 0.

BIOLOGICAL

Pneumococcal vaccine GSK2189242A (formulation 2)

One dose will be administered intramuscularly at Study Day 0.

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00896064 - Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults | Biotech Hunter | Biotech Hunter